Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEM-PRO
2024-514580-26-00Phase 2Completed
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in prostate cancer (PCa), sponsored by IRCCS Ospedale San Raffaele. Started Oct 2024; status: completed.
02
Drugs
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2024-514580-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514580-26-00.